No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LUCD Lucid Diagnostics
- 0.722
- +0.012+1.63%
Close Jun 18 16:00 ET
- 0.711
- -0.011-1.51%
Post 18:46 ET
37.84MMarket Cap-572P/E (TTM)
0.739High0.700Low90.37KVolume0.719Open0.710Pre Close65.34KTurnover0.52%Turnover RatioLossP/E (Static)52.42MShares1.72152wk High-1.17P/B12.48MFloat Cap0.63052wk Low--Dividend TTM17.29MShs Float13.520Historical High--Div YieldTTM5.44%Amplitude0.630Historical Low0.723Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | 4,000TH Firefighter Undergoes Lucid Diagnostics' Esoguard® Esophageal Precancer Testing
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Lowers Price Target to $7.5
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics with a Buy and lowers the price target from $8 to $7.5.
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $7.5
Ascendiant analyst Edward Woo maintains $Lucid Diagnostics(LUCD.US)$ with a buy rating, and adjusts the target price from $8 to $7.5.According to TipRanks data, the analyst has a success rate of 34.7%
Express News | Lucid Diagnostics Inc : Ascendiant Capital Markets Cuts Target Price to $7.5 From $8
Express News | Lucid Diagnostics Inc - Determined to Reschedule 2024 Annual Meeting of Stockholders for 11:00 A.m. Eastern Time on July 23
Comments
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing
PR Newswire· 2 mins ago
PR Newswire· 2 mins ago
1
2
$Lucid Diagnostics(LUCD.US$
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
2
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually.
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
1
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test![]()
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg